Literature DB >> 11572320

Clinical testing results and high patient satisfaction with a new needle-free device for growth hormone in young children.

J H Silverstein1, F T Murray, T Malasanos, S Myers, S B Johnson, K Frye, M Grossman.   

Abstract

Fifty children ages 4-10 yr with type 1 diabetes mellitus volunteered to participate in a study to evaluate and compare a new needle-free device developed for growth hormone delivery. Children answered descriptive questions related to nervousness and worry, hurt or pain, redness or bleeding, and stinging and wetness. Choices for answers for each of these five questions were none, a little, or a lot. None or a little was also combined to give a minimal category. Children also answered four questions that compared the needle-free device to their morning insulin needle injection in reference to ease of use, pain, nervousness, and overall preference. Half the children had single comfort rings inserted to increase the injection pressure. Results indicated no difference in question responses with or without pressure rings. Pain (92%), erythema (96%), worry (90%), stinging (86%) and wetness (96%) were minimal and significant (0.001 > p < 0.03) following all questions. Results of the comparative questionnaire indicated that the device was easier (p < 0.03) to use than needles and significantly preferred (p < 0.001) in 74% of children under age 10.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11572320     DOI: 10.1385/ENDO:15:1:015

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  5 in total

1.  The Medi-Jector II: efficacy and acceptability in insulin-dependent diabetic patients with and without needle phobia.

Authors:  C M Houtzagers; A P Visser; P A Berntzen; R J Heine; E A van der Veen
Journal:  Diabet Med       Date:  1988-03       Impact factor: 4.359

2.  Pharmacokinetics and pharmacodynamics of recombinant human growth hormone by subcutaneous jet- or needle-injection in patients with growth hormone deficiency.

Authors:  E C Houdijk; E Herdes; H A Delemarre-Van de Waal
Journal:  Acta Paediatr       Date:  1997-12       Impact factor: 2.299

3.  Pharmacokinetics and pharmacodynamics of a single dose of recombinant human growth hormone after subcutaneous administration by jet-injection: comparison with conventional needle-injection.

Authors:  A Verhagen; J T Ebels; A A Dogterom; J H Jonkman
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Painfulness of needle and jet injection in children with diabetes mellitus.

Authors:  U Schneider; R Birnbacher; E Schober
Journal:  Eur J Pediatr       Date:  1994-06       Impact factor: 3.183

5.  A survey of patient preference for insulin jet injectors versus needle and syringe.

Authors:  J R Denne; K L Andrews; D V Lees; W Mook
Journal:  Diabetes Educ       Date:  1992 May-Jun       Impact factor: 2.140

  5 in total
  3 in total

1.  Efficacy of needle-free administration of recombinant human growth hormone in adults with growth hormone deficiency.

Authors:  Alberto M Pereira; Agatha A van der Klaauw; Hans P F Koppeschaar; Jan W A Smit; Sjoerd W van Thiel; Jaap van Doorn; Nienke R Biermasz; Ferdinand Roelfsema; Johannes A Romijn
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

2.  Understanding and meeting the needs of those using growth hormone injection devices.

Authors:  Hervé Dumas; Paris Panayiotopoulos; Dorothy Parker; Vincent Pongpairochana
Journal:  BMC Endocr Disord       Date:  2006-10-11       Impact factor: 2.763

3.  Pharmacokinetics of recombinant human growth hormone administered by cool.click 2, a new needle-free device, compared with subcutaneous administration using a conventional syringe and needle.

Authors:  Chris Brearley; Anthony Priestley; James Leighton-Scott; Michel Christen
Journal:  BMC Clin Pharmacol       Date:  2007-10-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.